There’s a newly approved treatment for multiple myeloma that has returned after earlier therapy. The combination of Tecvayli ...

Clinical trial led by UAB researcher supports approval of new, potentially curative treatment for multiple myeloma ...

Johnson & Johnson’s standout trial results for its Tecvayli and Darzalex Faspro pairing in previously treated relapsed or refractory multiple myeloma have earned the company the third ultra-spe | FDA ...

For patients facing a multiple myeloma diagnosis, the journey is often defined by a search for the next line of defense. For survivor Julie Cohen, that search led her to the front lines of medical ...

Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy1 Teclistamab monotherapy delivered superior progression-free ...

Bristol Myers Squibb Announces Positive Phase 3 Data from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma ...

Bristol Myers Squibb’s mezigdomide has scored its first phase 3 win, with the Cereblon E3 ligase modulator (CELMoD) tied to a statistically significant improvement in progression-free survival (PFS) ...

Each year, approximately 36,000 people are diagnosed with the disease in the United States, according to the American Cancer ...

In second- or later-line setting, combination cut risk of disease progression or death by ...

Mezigdomide (a CELMoD) combined with carfilzomib/dexamethasone met the phase 3 primary endpoint, delivering statistically ...

Provisional license allows Rapid Novor to begin testing Canadian patients using a highly sensitive, non-invasive blood-based assay for measurable residual disease (MRD) monitoring. KITCHENER, ON, ...

Tibetan tingsha bells are used as a brief pre-event grounding intervention, leveraging sustained high-frequency resonance to ...